Innovative Pre-clinical Research

Synovo is a drug discovery company with a primary focus on inflammation and innate immune processes.
We are located in Tübingen, Germany which is both a major centre for basic research and also home to a vibrant bio-medical start-up scene.
We have two main business areas:

  • we provide drug discovery services in pharmacology, medicinal chemistry and bioanalytics, and,
  • we develop in-house novel therapeutics and related diagnostics

Our culture is focused on generating insight through inter-disciplinary, collaborative work with clients and partners.   
Within our team of nearly 50 people we have specialists in synthetic chemistry, pharmacology, analytics, immunology, neurology and biochemistry.  In addition, we have a broad network of research partners throughout the world collaborating with us in areas like basic disease mechanisms, drug formulation technology, surface modification and drug mode of action.

We welcome enquiries and we are proud of our reputation for helping colleagues and partners achieve their research goals. 

What we do

PHARMACEUTICAL SERVICES

Synovo offers the possibility of improving your pre-clinical data set. Take the opportunity to explore deeper parameters and learn more from your studies by adding our services to your projects.

 

 

Learn more about our

SERVICES

 

 

INNOVATION

We are committed to contribute to health improvement by developing novel therapeutic options for global unmet needs.

 

 

 

Learn more about our

PROJECTS

 

TEAM

The Synovo family shares a common interest toward developing science-driven mind changing ideas, by interdisciplinary and creative team work. Moreover we are aware of our place in the local community, trying to exemplify an active lifestyle.

 

Learn more about our

TEAMSCIENCE

Latest news

Pressemitteilung – Forschung zu Covid-19

Press Release English Statement   Pressemitteilung   Synovo gibt die Entwicklung seines Therapiekandidaten für virale Covid-19-Lungenentzündung bekannt 24.03.2020, Tübingen, Deutschland   Synovo GmbH wird sich auf die Entwicklung von SYD015 konzentrieren. SYD015 ist ein Wirkstoffkandidat, der in ersten Tests zeigen konnte, dass mit ihm akute virale und bakterielle Lungenentzündungen sowie akutes Lungenversagen (acute respiratory distress […]

Synovo at the itdesign-Nikolauslauf Tübingen

Synovo had a successful showing at the 44th itdesign-Nikolauslauf, which took place December 8th in our beautiful hometown Tübingen. The Synovo running team took the 6th place overall out of 93 teams in total. Five runners were counting towards the team – Synovos fastest runner was Timo Göhler, who was able to finish third overall […]

Synovo at the 46th BMW Berlin Marathon

Michael Burnet and Timo Göhler, two runners of Synovos strong running team were participating at the 46th BMW Berlin Marathon, which took place on September 29th, 2019. While Michael just missed out on a sub 3 hour finish due to some muscular struggles in the second half, Timo was able to finish as 4th fastest […]

See all our news

We believe in

  • Research commitment. Users/patients focus. Quality and reliability.
  • Respect and integrity. Work-life balance.
  • Diversity.
  • Interdisciplinary team. Open and constant flow of knowledge.
  • Collaborative leadership. Transparent networking.
  • Flexibility and Creative Innovation. Challenge acceptance.
  • Education and training. Modern and traditional methods.
  • Personal growth and initiative.
Join in